High EZH2 expression a marker for death risk in RCC

FROM JOURNAL OF CLINICAL ONCOLOGY In patients with localized clear cell renal cell carcinoma ...

PROTECT trial: No DFS benefit with adjuvant pazopanib for high-risk RCC

FROM JOURNAL OF CLINICAL ONCOLOGY Adjuvant pazopanib provided no disease-free survival benefit compared with ...

[sam_pro id=0_12 codes="true"]
[sam_pro id=0_6 codes="false"]